Abiraterone [ABI2]

For the treatment of patients with hormone-relapsed (castrate-resistant) metastatic prostate cancer with disease progression during or following treatment with docetaxel-containing chemotherapy where the following criteria have been met:

1. This application is being made by and the first cycle of systemic anti-cancer therapy with abiraterone will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. This patient either has a proven histological or cytological diagnosis of adenocarcinoma of the prostate or has presented with a clinical picture consistent with metastatic prostate cancer with both widespread bone metastases radiologically typical of prostate cancer and a serum PSA of ≥50 ng/mL.
3. This patient has hormone-relapsed (castration-resistant) metastatic prostate cancer.
4. The patient has been treated with docetaxel-containing chemotherapy and has progressed during or following treatment.
5. One of the following applies to this patient as regards any previous use of 2nd generation receptor inhibitors (such as enzalutamide, darolutamide or apalutamide) or CYP17 enzyme inhibitors (such as abiraterone). Please enter below as to which scenario applies to this patient:

• the patient has not previously received any treatment with enzalutamide or darolutamide or apalutamide or abiraterone or
• the patient has previously received enzalutamide for this same post-chemotherapy indication in hormone-relapsed (castrate-resistant) prostate cancer but it was stopped due to dose-limiting toxicity and in the clear absence of disease progression

6. Abiraterone is to be given in combination with prednisolone
7. The patient has an ECOG performance status (PS) of 0 or 1 or 2.
8. Abiraterone is to be continued until disease progression or unacceptable toxicity or patient choice to stop treatment.
9. Where a treatment break of more than 6 weeks beyond the expected 4-weekly cycle length is needed, I will complete a treatment break approval form requesting a restart to treatment.
10. Abiraterone is to be otherwise used as set out in its Summary of Product Characteristics.

NHS funded From: 25 September 2012

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: TA259 (27 June 2012)

Current Form Version

Note

The data on this page was produced using version 1.381 of the CDF list, downloaded from NHS England’s website on 08 January 2026 at 14:00.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.

• ABI2_prior_to_cdf_1.361
• ABI2_prior_to_cdf_1.381